Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study

详细信息    查看全文

• 作者：Pei Chen ; Huiyu Feng ; Juan Deng ; Yufei Luo ; Li Qiu ; Changyi Ou…
• 关键词：Myasthenia gravis ; Leflunomide ; Corticosteroid ; dependent ; QMG ; ADL
• 刊名：Journal of Neurology
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：263
• 期：1
• 页码：83-88
• 全文大小：381 KB
• 参考文献：1.Rowin J, Meriggioli MN, Tuzun E, Leurgans S, Christadoss P (2004) Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 63:2390–2392CrossRef PubMed
  2.Ponseti JM, Azem J, Fort JM, Lopez-Cano M, Vilallonga R, Buera M, Cervera C, Armengol M (2005) Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 64:1641–1643CrossRef PubMed
  3.Kawaguchi N, Yoshiyama Y, Nemoto Y, Munakata S, Fukutake T, Hattori T (2004) Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin 20:1269–1273CrossRef PubMed
  4.Nagaishi A, Yukitake M, Kuroda Y (2008) Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus. Intern Med 47:731–736CrossRef PubMed
  5.Griffin R, Levine T, Mozaffar T, Nowak R, Pulley M, Dimachkie M, Nicolle M (2015) Efficacy and safety of IGIV-C in corticosteroid dependent patients with generalized myasthenia gravis. https://​www.​clinicaltrials.​gov/​ct2/​show/​NCT02473965
  6.Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G (1987) Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316:719–724CrossRef PubMed
  7.Palace J, Newsom-Davis J, Lecky B (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50:1778–1783CrossRef PubMed
  8.Sanders DB, Evoli A (2010) Immunosuppressive therapies in myasthenia gravis. Autoimmunity 43:428–435CrossRef PubMed
  9.Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8:475–490PubMedCentral CrossRef PubMed
  10.Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023–1036CrossRef PubMed
  11.Cherwinski HM, Byars N, Ballaron SJ, Nakano GM, Young JM, Ransom JT (1995) Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res 44:317–322CrossRef PubMed
  12.O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365:1293–1303CrossRef PubMed
  13.Confavreux C, O’Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L (2014) Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13:247–256CrossRef PubMed
  14.O’Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R (2006) A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66:894–900CrossRef PubMed
  15.Vidic-Dankovic B, Kosec D, Damjanovic M, Apostolski S, Isakovic K, Bartlett RR (1995) Leflunomide prevents the development of experimentally induced myasthenia gravis. Int J Immunopharmacol 17(4):273–281CrossRef PubMed
  16.Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge HW, European Federation of Neurological S (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17:893–902CrossRef PubMed
  17.Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A (2008) IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis. Brain 131:1940–1952PubMedCentral CrossRef PubMed
  18.Cossins J, Belaya K, Zoltowska K, Koneczny I, Maxwell S, Jacobson L, Leite MI, Waters P, Vincent A, Beeson D (2012) The search for new antigenic targets in myasthenia gravis. Ann N Y Acad Sci 1275:123–128CrossRef PubMed
  19.Burns TM (2010) History of outcome measures for myasthenia gravis. Muscle Nerve 42:5–13CrossRef PubMed
  20.Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB (2001) Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 56:97–99CrossRef PubMed
  21.Poor G, Strand V, Leflunomide Multinational Study G (2004) Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial. Rheumatol (Oxford) 43:744–749CrossRef
  22.van Riel PL, Smolen JS, Emery P, Kalden JR, Dougados M, Strand CV, Breedveld FC (2004) Leflunomide: a manageable safety profile. J Rheumatol Suppl 71:21–24PubMed
  23.Alcorn N, Saunders S, Madhok R (2009) Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 32:1123–1134CrossRef PubMed
  24.Keen HI, Conaghan PG, Tett SE (2013) Safety evaluation of leflunomide in rheumatoid arthritis. Expert Opin Drug Saf 12:581–588CrossRef PubMed
  25.Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, Melms A, Nicolle MW, Solomons N, Richman DP (2008) An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71:400–406CrossRef PubMed
  26.The Muscle Study Group (2008) A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 71:394–399CrossRef
  27.Sanders DB, Siddiqi ZA (2008) Lessons from two trials of mycophenolate mofetil in myasthenia gravis. Ann N Y Acad Sci 1132:249–253CrossRef PubMed
  
• 作者单位：Pei Chen (1)
  Huiyu Feng (1)
  Juan Deng (1)
  Yufei Luo (1)
  Li Qiu (1)
  Changyi Ou (1)
  Weibin Liu (1)
  
  1. Department of Neurology, The First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan 2nd Rd, Yuexiu, Guangzhou, Guangdong, People’s Republic of China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Neurology
  Neurosciences
  Neuroradiology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1459

文摘

Leflunomide is an effective drug used in the treatment of rheumatoid arthritis. Here we report the findings of an open-label pilot study, which found that leflunomide is also an effective treatment for myasthenia gravis (MG). This study recruited 15 corticosteroid-dependent MG patients. For 6 months, leflunomide 20 mg was given to these patients daily along with prednisone. The quantitative myasthenia gravis (QMG) scores and MG activities of daily living (MG-ADL) profiles were measured in these MG patients. After 6 months of treatment, 9 of the 15 patients enrolled in this study showed improvements in both QMG and MG-ADL. The mean QMG scores (13.4 to 8.5) and MG-ADL profiles (5.8 to 2.8) were significantly decreased (P = 0.01, 0.006 respectively). Furthermore, we found that the mean corticosteroid doses were reduced after treatment with leflunomide (24.3 to 12.3 mg per day). Leflunomide is a well-tolerated and efficacious treatment for corticosteroid-dependent MG, which may also enable lower doses of corticosteroids to be administered.